Related Experiment Video
Updated: Feb 9, 2026

Analyzing Starvation-Induced Autophagy in the Drosophila melanogaster Larval Fat Body
Published on: August 4, 2022
Autophagy inhibition enhances celecoxib-induced apoptosis in osteosarcoma
Pingting Zhou1, Yanyan Li1, Bo Li2
1a Department of Radiation Oncology , Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine , Shanghai , China.
Abstract:
Osteosarcoma (OS) is the most prevalent bone malignancy in childhood and adolescence, with highly aggressive and early systemic metastases. Here, we reported that celecoxib, a selective COX-2 inhibitor in the NSAID class, exhibits strong antitumor activity in dose dependent manner in two OS cell lines-143B and U2OS. We showed that celecoxib inhibits OS cell growth, causes G0/G1-phase arrest, modulates apoptosis and autophagy and reduces migration in OS cells. In addition, the results of fluorescent mitochondrial probe JC-1 test indicated that the mitochondrial pathway mediates celecoxib-induced apoptosis. Significantly, the autophagy inhibitor CQ combined with celecoxib causes greater cell proliferation inhibition and apoptosis. Pharmacologic inhibition of autophagy with another potent autophagy inhibitor SAR405 also enhances celecoxib-mediated suppression of cell viability. These results were confirmed with shRNAs targeting the autophagy-related gene Atg5. In OS tumor xenografts in vivo, celecoxib also presents antitumor activity. Taken together, our results shed light on the function and mechanism of antitumor action of celecoxib for treatment of OS patients.
Insights
Celecoxib, a COX-2 inhibitor, demonstrates significant antitumor effects against osteosarcoma (OS) by inhibiting cell growth and promoting apoptosis. Combining celecoxib with autophagy inhibitors further enhances its effectiveness in treating this aggressive bone cancer.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Osteosarcoma (OS) is a prevalent and aggressive bone cancer in children and adolescents, characterized by early metastasis.
- Effective therapeutic strategies for OS remain a critical unmet need.
Purpose of the Study:
- To investigate the antitumor activity and underlying mechanisms of celecoxib, a selective COX-2 inhibitor, in osteosarcoma.
- To evaluate the potential synergistic effects of combining celecoxib with autophagy inhibitors.
Main Methods:
- In vitro studies using OS cell lines (143B, U2OS) treated with celecoxib.
- Assessment of cell viability, cell cycle progression, apoptosis, mitochondrial pathways, and migration.
- In vivo studies using OS tumor xenografts.
- Combination treatments with autophagy inhibitors (CQ, SAR405) and genetic inhibition (shRNA targeting Atg5).
Main Results:
- Celecoxib exhibited dose-dependent inhibition of OS cell growth, G0/G1-phase arrest, and reduced migration.
- Celecoxib induced apoptosis via the mitochondrial pathway.
- Combination therapy with autophagy inhibitors (CQ, SAR405) or Atg5 knockdown significantly enhanced celecoxib's antiproliferative and pro-apoptotic effects.
- Celecoxib demonstrated antitumor activity in vivo xenograft models.
Conclusions:
- Celecoxib possesses significant antitumor activity against osteosarcoma.
- The combination of celecoxib with autophagy inhibition presents a promising therapeutic strategy for osteosarcoma treatment.
- Understanding these mechanisms provides insights for developing novel therapeutic approaches for OS patients.
More Related Videos
04:25Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
08:00Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
Related Concept Videos
Apoptosis
Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
Feedback Inhibition
Enzyme Inhibition
Self-Evaluation: Self-Enhancement and Self-Verification
Inhibition of Cdk Activity